MCID: DFF005
MIFTS: 64

Diffuse Large B-Cell Lymphoma

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Diffuse Large B-Cell Lymphoma

MalaCards integrated aliases for Diffuse Large B-Cell Lymphoma:

Name: Diffuse Large B-Cell Lymphoma 37 12 49 14 69
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified 69
Large B-Cell Diffuse Lymphoma 72
Dlbcl 49

Classifications:



External Ids:

Disease Ontology 12 DOID:0050745
ICD10 32 C83.3

Summaries for Diffuse Large B-Cell Lymphoma

NIH Rare Diseases : 49 Diffuse large B-cell lymphoma (DLBCL), a form of non-Hodgkin lymphoma, is the most common blood cancer. Lymphomas occur when cells of the immune system, known as B lymphocytes, grow and multiply uncontrollably. DLBCL occurs mostly in adults and is a fast-growing (aggressive) lymphoma. It can start in the lymph nodes or outside of the lymphatic system in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain. Often, the first sign of DLBCL is a painless rapid swelling in the neck, armpit, abdomen, or groin caused by enlarged lymph nodes. For some people, the swelling may be painful. Other symptoms include night sweats, unexplained fevers, and weight loss. Treatment may differ depending on the location of the tumor and the subtype of lymphoma. For those who have advanced DCBCL and have not been treated previously, a combination of chemotherapy and the monoclonal antibody rituximab (Rituxan) (R-CHOP) may be tried.. In addition, as of October 2017, axicabtagene ciloleucel (brand name: Yescarta), a type of gene therapy, has been approved by the United States FDA to treat DCBCL that is not responding to at least two treatment attempts or has returned after being treated before. A stem cell transplant may also be an option if DLBCL returns or relapses. Last updated: 11/9/2017

MalaCards based summary : Diffuse Large B-Cell Lymphoma, also known as diffuse large b-cell lymphoma, not otherwise specified, is related to primary cutaneous diffuse large b-cell lymphoma, leg type and t-cell/histiocyte rich large b cell lymphoma. An important gene associated with Diffuse Large B-Cell Lymphoma is BCL6 (B Cell CLL/Lymphoma 6), and among its related pathways/superpathways are Apoptosis Modulation and Signaling and Downstream signaling events of B Cell Receptor (BCR). The drugs rituximab and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are immune system and hematopoietic system

Disease Ontology : 12 A B-cell lymphoma that is a cancer of B cells presenting as an aggressive tumour which can arise in virtually any part of the body.

Wikipedia : 72 Diffuse large B-cell lymphoma (DLBCL or DLBL) is a cancer of B cells, a type of white blood cell... more...

Related Diseases for Diffuse Large B-Cell Lymphoma

Diseases related to Diffuse Large B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 325)
# Related Disease Score Top Affiliating Genes
1 primary cutaneous diffuse large b-cell lymphoma, leg type 34.9 IRF4 MYD88
2 t-cell/histiocyte rich large b cell lymphoma 33.2 BCL6 MME TNFRSF8
3 richter's syndrome 32.9 CD5 IRF4 MYC TP53
4 follicular lymphoma 32.6 BCL6 CD5 IRF4 MME MYC ZC3H12D
5 mediastinal gray zone lymphoma 32.5 BCL6 REL TNFRSF8
6 primary mediastinal large b-cell lymphoma 32.3 BCL6 FOXP1 IRF4
7 intravascular large b-cell lymphoma 32.2 BCL6 CD5 MME
8 lymphoma 31.6 BCL6 EZH2 GCSAM MALT1 MYC REL
9 angioimmunoblastic t-cell lymphoma 31.2 BCL6 MME
10 lymphoma, hodgkin, classic 31.1 BCL6 IRF4 REL TNFRSF8
11 primary effusion lymphoma 31.0 BCL6 IRF4 MYC
12 nodal marginal zone b-cell lymphoma 30.6 BCL6 MALT1
13 lymphoblastic lymphoma 30.6 BCL6 CD5 MME
14 myeloma, multiple 30.6 CDK4 IRF4 MYC TP53
15 breast lymphoma 30.5 BCL6 CD5
16 marginal zone b-cell lymphoma 30.5 BCL6 CD5 IRF4 MALT1 MME MYD88
17 leukemia, chronic lymphocytic 30.4 BCL6 CD5 MDM2 TNFRSF8 TP53
18 splenic marginal zone lymphoma 30.4 BCL6 CD5 MALT1
19 b-cell lymphomas 30.4 BCL6 CARD11 CD5 FOXP1 IRF4 MALT1
20 lymphoma, mucosa-associated lymphoid type 30.3 BCL6 CARD11 CD5 FOXP1 IRF4 MALT1
21 mantle cell lymphoma 30.3 BCL6 CD5 CDK4 EZH2 MDM2 MME
22 central nervous system lymphoma 30.2 BCL6 FOXP1 MALT1 MYD88 PRDM1 TP53
23 prostate lymphoma 30.2 CD5 MALT1
24 leukemia, acute myeloid 30.1 CD5 EZH2 MDM2 MME MYC TP53
25 adult lymphoma 29.8 CD5 MYC PRDM1 TNFRSF8
26 lymphoma, non-hodgkin, familial 29.3 BCL6 CD5 IRF4 MALT1 MDM2 MME
27 relapsed/refractory diffuse large b-cell lymphoma 12.7
28 epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly 12.6
29 diffuse large b-cell lymphoma of the central nervous system 12.6
30 diffuse large b-cell lymphoma with chronic inflammation 12.5
31 gray zone lymphoma 11.7
32 reticulosarcoma 11.4
33 plasmablastic lymphoma 11.0
34 primary central nervous system lymphoma 10.9
35 chops syndrome 10.9
36 ring chromosome y syndrome 10.8
37 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.7 BCL6 MYC
38 gallbladder lymphoma 10.6 BCL6 MME
39 heart lymphoma 10.6 BCL6 MME
40 actinic cheilitis 10.6 MDM2 TP53
41 primary cutaneous marginal zone b-cell lymphoma 10.5 IRF4 MALT1
42 tracheal lymphoma 10.5 CD5 MME
43 malignant fibrous histiocytoma of bone 10.5 CDK4 MDM2 MYC
44 ring chromosome 7 10.5 CDK4 MDM2 TP53
45 alk-positive large b-cell lymphoma 10.5
46 acquired immunodeficiency syndrome 10.5 BCL6 MYC TP53
47 undifferentiated embryonal sarcoma of the liver 10.5 CDK4 MDM2
48 periosteal osteogenic sarcoma 10.5 CDK4 MDM2 TP53
49 dedifferentiated liposarcoma 10.5 CDK4 MDM2 TP53
50 fibrosarcoma of bone 10.5 CDK4 MDM2 MYC

Graphical network of the top 20 diseases related to Diffuse Large B-Cell Lymphoma:



Diseases related to Diffuse Large B-Cell Lymphoma

Symptoms & Phenotypes for Diffuse Large B-Cell Lymphoma

MGI Mouse Phenotypes related to Diffuse Large B-Cell Lymphoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.32 CDK4 MALT1 MDM2 EZH2 BCL6 GCSAM
2 hematopoietic system MP:0005397 10.31 CDK4 MALT1 MDM2 EZH2 BCL6 IRF4
3 cardiovascular system MP:0005385 10.18 CDK4 MDM2 EZH2 BCL6 LMO2 TP53
4 endocrine/exocrine gland MP:0005379 10.09 CDK4 MDM2 EZH2 BCL6 TP53 MYD88
5 embryo MP:0005380 10.06 CDK4 MDM2 EZH2 LMO2 TP53 PRDM1
6 integument MP:0010771 10.02 CDK4 MDM2 EZH2 CARD11 CD5 LMO2
7 liver/biliary system MP:0005370 9.91 CDK4 MDM2 BCL6 LMO2 PRDM1 MME
8 neoplasm MP:0002006 9.81 CDK4 MDM2 EZH2 IRF4 LMO2 PRDM1
9 no phenotypic analysis MP:0003012 9.56 MDM2 EZH2 BCL6 CD5 MYD88 PRDM1
10 normal MP:0002873 9.28 CDK4 MDM2 EZH2 BCL6 CD5 TP53

Drugs & Therapeutics for Diffuse Large B-Cell Lymphoma

Drugs for Diffuse Large B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 528)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 147-94-4 6253
4
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
5
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
6
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
7
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
8 Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
10
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 23214-92-8 31703
11
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
12
Ifosfamide Approved Phase 4,Phase 3,Phase 1,Phase 2 3778-73-2 3690
13
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
14
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
15
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2 53643-48-4, 59917-39-4 40839
16
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1 15663-27-1 2767 441203 84093
17
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 657311 5754
18
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
21
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 31703
22 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
25 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
29 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
38 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1
39 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
41 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
44 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Isophosphamide mustard Phase 4,Phase 3,Phase 1,Phase 2 0
49 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
50 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1278)

# Name Status NCT ID Phase Drugs
1 Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old. Unknown status NCT00429065 Phase 4 Rituximab
2 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
3 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
4 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
5 Treatment of Diffuse Large B Cell Lymphoma Recruiting NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
6 Treatment of Relapsed /Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03376958 Phase 4 Apatinib
7 Reduced Chemotherapy in Low Risk DLBCL Recruiting NCT02752815 Phase 4 Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
8 Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients Unknown status NCT00846157 Phase 3
9 Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. Unknown status NCT01805557 Phase 2, Phase 3 R-DHAP;BR-DHAP
10 Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma Unknown status NCT00499018 Phase 3 Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;ARA-C;VP-16;Ciclofosfamide;Doxorubicina;Vincristina
11 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
12 Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R Unknown status NCT00322218 Phase 3 Zevalin Therapeutic Regimen
13 TREatment of degeNerative and Neoplastic Diseases With Rituximab Unknown status NCT01277172 Phase 2, Phase 3
14 Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
15 Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
16 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
17 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
18 Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
19 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
20 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
21 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
22 Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00003815 Phase 3 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
23 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
24 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
25 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
26 High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003578 Phase 3 CHOP regimen;carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisone;vincristine sulfate
27 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
28 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
29 A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
30 ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1 Completed NCT00140595 Phase 3 rituximab;doxorubicin;cyclophosphamide
31 R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma Completed NCT00144755 Phase 3 Darbepoetin alfa
32 Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV Completed NCT00286832 Phase 3
33 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3 Intravenous;Bortezomib
34 A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma Completed NCT01649856 Phase 3 CHOP;rituximab [MabThera/Rituxan];rituximab [MabThera/Rituxan]
35 ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma Completed NCT00169130 Phase 2, Phase 3 doxorubicin;cyclophosphamide
36 Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma Completed NCT02268045 Phase 3
37 R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma Completed NCT00137995 Phase 3 Rituximab;Etoposide;Carboplatine;Ifosfamide + Mesna;Cisplatine;Cytosine Arabinoside;Dexamethasone;BCNU;Etoposide;Cytarabine;Melphalan
38 R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL Completed NCT01148446 Phase 3 Cyclophosphamide;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Prednisone;Epirubicin;Vinblastine;Rituximab;G-CSF
39 Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma Completed NCT00052923 Phase 3 carmustine;cyclophosphamide;etoposide
40 Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma Completed NCT01014208 Phase 3 OFATUMUMAB + DHAP;RITUXIMAB + DHAP
41 Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma Completed NCT01459887 Phase 3 CHOP combined with CMAB304;CHOP, CMAB304
42 MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Mabthera/Rituxan During First-Line Treatment for Lymphoma. Completed NCT01987505 Phase 3 rituximab [MabThera/Rituxan]
43 Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma Completed NCT00566228 Phase 3
44 Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL. Completed NCT00355199 Phase 3 Rituximab-HDS;Rituximab-CHOP
45 Zevalin-beam for Aggressive Lymphoma Completed NCT00491491 Phase 3 ibritumomab tiuxetan
46 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3 Rituximab
47 A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) Completed NCT00719472 Phase 3 Rituximab;CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone);CVP (cyclophosphamide, vincristine, prednisone);Analgesic/antipyretic and antihistamine drugs
48 PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin Completed NCT00332202 Phase 3 enzastaurin;placebo
49 Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00012051 Phase 3 carmustine;cisplatin;cytarabine;dexamethasone;etoposide;ifosfamide;melphalan;methotrexate
50 Combination Chemotherapy With or Without Rituximab in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00064116 Phase 3 CHOP regimen

Search NIH Clinical Center for Diffuse Large B-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diffuse Large B-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Diffuse Large B-Cell Lymphoma

Anatomical Context for Diffuse Large B-Cell Lymphoma

MalaCards organs/tissues related to Diffuse Large B-Cell Lymphoma:

38
B Cells, Bone, Bone Marrow, T Cells, Liver, Testes, Kidney

Publications for Diffuse Large B-Cell Lymphoma

Articles related to Diffuse Large B-Cell Lymphoma:

(show top 50) (show all 1866)
# Title Authors Year
1
Erratum: Epperla N, Maddocks KJ, Salhab M, et al. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer. 2017;123:4411-4418. ( 29406586 )
2018
2
Complete response of diffuse large B-cell lymphoma after direct-acting antiviral therapy for hepatitis C virus. ( 29432921 )
2018
3
Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER-Medicare Cohort. ( 29273217 )
2018
4
Some diffuse large B-cell lymphomas (DLBCLs) present with clone-dependent TTF-1 positivity. ( 29393528 )
2018
5
Primary breast diffuse large B-cell lymphoma: a population-based study from 1975 to 2014. ( 29423097 )
2018
6
Over-activated PD-1/PD-L1 axis facilitates the chemoresistance of diffuse large B-cell lymphoma cells to the CHOP regimen. ( 29435074 )
2018
7
Systemic diffuse large B-cell lymphoma masquerading as neovascular glaucoma. ( 29380792 )
2018
8
Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin. ( 28583033 )
2018
9
PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. ( 29112015 )
2018
10
Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B cell Lymphoma and Acute Myeloid Leukemia: A Report of Two Cases. ( 29321428 )
2018
11
Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma. ( 29427185 )
2018
12
Anti-ZIC4 associated paraneoplastic cerebellar degeneration in a patient with both diffuse large B-cell lymphoma and incidental smoldering multiple myeloma. ( 29249374 )
2018
13
Chemotherapy is administered to a minority of hospitalized patients with diffuse large B-cell lymphoma and is associated with less likelihood of death during hospitalization. ( 29438924 )
2018
14
Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.<i>Blood</i>. 2017;130(16):1800-1808. ( 29437609 )
2018
15
Primary Liver Diffuse Large B-Cell Lymphoma following Complete Response for Hepatitis C Infection after Direct Antiviral Therapy. ( 29393087 )
2018
16
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. ( 29416618 )
2018
17
Targetable Metabolic Vulnerability in Diffuse Large B-Cell Lymphoma. ( 29397369 )
2018
18
Computer-driven quantitative image analysis in the assessment of tumor cell and T cell features in diffuse large B cell lymphomas. ( 29362889 )
2018
19
A Rare Manifestation of Primary Bone Lymphoma: Solitary Diffuse Large B-Cell Lymphoma of the Little Finger. ( 29398333 )
2018
20
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. ( 29419431 )
2018
21
Concurrent mucosa-associated lymphoid tissue lymphoma with diffuse large B-cell lymphoma transformation and Hodgkin lymphoma of the neck. ( 29427189 )
2018
22
High frequency and prognostic value of<i>MYD88</i>L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment. ( 29403563 )
2018
23
Interim FDG PET/CT in primary mediastinal diffuse large B-cell lymphoma: really almost useless procedure? ( 29397402 )
2018
24
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. ( 29413279 )
2018
25
Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma. ( 29428948 )
2018
26
De Novo CD5-Positive Primary Gastric Diffuse Large B-Cell Lymphoma Coexpressing MYC and BCL6: Towards a Proper Subset of Double-Hit, Triple-Hit and, Maybe, Quadruple-Hit B-Cell Lymphomas? ( 29399573 )
2018
27
Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma. ( 28103885 )
2017
28
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. ( 27568520 )
2017
29
mTOR activity in AIDS-related diffuse large B-cell lymphoma. ( 28192480 )
2017
30
Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. ( 28351934 )
2017
31
Learning from the Failures of Drug Discovery in B-Cell Non-Hodgkin Lymphomas and Perspectives for the Future: Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma as Two Ends of a Spectrum in Drug Development. ( 28494631 )
2017
32
Diffuse large B-cell lymphoma of the lung in a patient with nonspecific interstitial pneumonia. ( 28867466 )
2017
33
Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort. ( 28302137 )
2017
34
A Case of Therapy-Related Acute Leukemia With Mixed Phenotype With BCR-ABL1 After Treatment of Diffuse Large B-Cell Lymphoma. ( 28029006 )
2017
35
High KIF2A expression predicts unfavorable prognosis in diffuse large B cell lymphoma. ( 28616658 )
2017
36
ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP. ( 28938556 )
2017
37
Nonregenerative immune-mediated anemia associated with a diffuse large B-cell lymphoma in a captive jaguar (Panthera onca). ( 28902958 )
2017
38
Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS). ( 27775850 )
2017
39
CD109, a negative regulator of TGF-I^ signaling, is a putative risk marker in diffuse large B-cell lymphoma. ( 28032275 )
2017
40
Composite lymphoma with coexistence of diffuse large B-cell lymphoma and anaplastic large cell lymphoma: Diagnostic pitfalls. ( 28631654 )
2017
41
A Case of Primary Bone Marrow Diffuse Large B-cell Lymphoma Presenting With Fibrillar Projections and Hemophagocytic Lymphohistiocytosis. ( 28840996 )
2017
42
A case report of concurrent embryonal rhabdomyosarcoma and diffuse large B-cell lymphoma in an adult without identifiable cancer predisposition. ( 28194276 )
2017
43
Prognostic Value of the Pretreatment Advanced Lung Cancer Inflammation Index (ALI) in Diffuse Large B Cell Lymphoma Patients Treated with R-CHOP Chemotherapy. ( 28076862 )
2017
44
Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study. ( 28507339 )
2017
45
Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09). ( 28076329 )
2017
46
A new diagnostic marker for differentiating multicentric gliomas from multiple intracranial diffuse large B-cell lymphomas on 18F-FDG PET images. ( 28796066 )
2017
47
The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. ( 28403071 )
2017
48
Inflammatory Biomarkers in Diffuse Large B-Cell Lymphoma: Time for Extending the Established Prognosis Scores? ( 28076864 )
2017
49
Methylation changes of SIRT1, KLF4, DAPK1 and SPG20 in B-lymphocytes derived from follicular and diffuse large B-cell lymphoma. ( 28324774 )
2017
50
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Spontaneous Regression After Biopsy. ( 28926365 )
2017

Variations for Diffuse Large B-Cell Lymphoma

Cosmic variations for Diffuse Large B-Cell Lymphoma:

9 (show top 50) (show all 140)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10654 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.637C>T p.R213* 7
2 COSM43956 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.700T>A p.Y234N 7
3 COSM10656 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.742C>T p.R248W 7
4 COSM43848 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.472C>T p.R158C 7
5 COSM10834 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.711G>A p.M237I 7
6 COSM10662 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.743G>A p.R248Q 7
7 COSM43833 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.578A>C p.H193P 7
8 COSM44692 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.526T>G p.C176G 7
9 COSM45626 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.501G>T p.Q167H 7
10 COSM45773 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.583A>C p.I195L 7
11 COSM43901 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.421T>C p.C141R 7
12 COSM11564 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.742C>G p.R248G 7
13 COSM11059 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.713G>A p.C238Y 7
14 COSM45780 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.429G>T p.V143V 7
15 COSM44463 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.848G>T p.R283L 7
16 COSM10991 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.396G>T p.K132N 7
17 COSM10659 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.817C>T p.R273C 7
18 COSM43967 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.751A>T p.I251F 7
19 COSM43684 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.720T>G p.S240R 7
20 COSM10777 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.715A>G p.N239D 7
21 COSM43733 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.777C>T p.D259D 7
22 COSM10648 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.524G>A p.R175H 7
23 COSM43842 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.770T>C p.L257P 7
24 COSM10742 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.578A>G p.H193R 7
25 COSM44327 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.518T>C p.V173A 7
26 COSM43947 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.614A>G p.Y205C 7
27 COSM10758 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.659A>G p.Y220C 7
28 COSM43936 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.857A>T p.E286V 7
29 COSM6932 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.733G>A p.G245S 7
30 COSM43970 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.380C>A p.S127Y 7
31 COSM45416 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.524G>C p.R175P 7
32 COSM10687 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.527G>A p.C176Y 7
33 COSM10690 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.473G>A p.R158H 7
34 COSM44948 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.526T>C p.C176R 7
35 COSM45627 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.486C>T p.I162I 7
36 COSM10996 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.511G>T p.E171* 7
37 COSM10813 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.394A>G p.K132E 7
38 COSM44338 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.845G>A p.R282Q 7
39 COSM11196 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.734G>T p.G245V 7
40 COSM44821 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.412G>A p.A138T 7
41 COSM43899 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.434T>C p.L145P 7
42 COSM11287 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.839G>T p.R280I 7
43 COSM44171 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.840A>T p.R280S 7
44 COSM43850 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.659A>C p.Y220S 7
45 COSM43559 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.517G>T p.V173L 7
46 COSM10704 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.844C>T p.R282W 7
47 COSM43896 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.818G>C p.R273P 7
48 COSM10647 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.404G>T p.C135F 7
49 COSM43903 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.470T>G p.V157G 7
50 COSM44535 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.761T>A p.I254N 7

Copy number variations for Diffuse Large B-Cell Lymphoma from CNVD:

7 (show top 50) (show all 118)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13828 1 1 84900000 Loss Diffuse large b-cell lymphoma
2 17406 1 142600000 249250621 Gain Diffuse large b-cell lymphoma
3 20082 1 15300000 163800000 Gain Diffuse large b-cell lymphoma
4 38345 10 101900000 103000000 Gain Diffuse large b-cell lymphoma
5 38773 10 104900000 105800000 Gain Diffuse large b-cell lymphoma
6 38901 10 105800000 121700000 Loss Diffuse large b-cell lymphoma
7 40597 10 130600000 135534747 Loss Diffuse large b-cell lymphoma
8 43294 10 46100000 64500000 Loss Diffuse large b-cell lymphoma
9 48479 11 1 43500000 Gain Diffuse large b-cell lymphoma
10 51204 11 123900000 135006516 Loss Diffuse large b-cell lymphoma
11 53206 11 26100000 36400000 Loss Diffuse large b-cell lymphoma
12 55792 11 55700000 135006516 Gain Diffuse large b-cell lymphoma
13 64291 12 12600000 14800000 Gain CDKN1B Diffuse large b-cell lymphoma
14 70914 12 66000000 69800000 Gain MDM2 Diffuse large b-cell lymphoma
15 74343 13 104800000 110300000 Loss Diffuse large b-cell lymphoma
16 74383 13 105800000 109100000 Loss Diffuse large b-cell lymphoma
17 75387 13 19500000 55300000 Gain Diffuse large b-cell lymphoma
18 76712 13 35500000 75400000 Loss Diffuse large b-cell lymphoma
19 79280 13 68600000 115169878 Gain Diffuse large b-cell lymphoma
20 86223 14 55800000 61200000 Loss Diffuse large b-cell lymphoma
21 88116 14 84900000 107349540 Loss Diffuse large b-cell lymphoma
22 90236 15 20700000 102531392 Loss Diffuse large b-cell lymphoma
23 97251 16 1 34600000 Gain Diffuse large b-cell lymphoma
24 97373 16 1 7900000 Gain ABCA3 Diffuse large b-cell lymphoma
25 97375 16 1 7900000 Gain DCI Diffuse large b-cell lymphoma
26 97377 16 1 7900000 Gain E4F1 Diffuse large b-cell lymphoma
27 97379 16 1 7900000 Gain HAGH Diffuse large b-cell lymphoma
28 97381 16 1 7900000 Gain IGFALS Diffuse large b-cell lymphoma
29 97383 16 1 7900000 Gain MRPS34 Diffuse large b-cell lymphoma
30 97385 16 1 7900000 Gain NME3 Diffuse large b-cell lymphoma
31 97387 16 1 7900000 Gain NUBP2 Diffuse large b-cell lymphoma
32 97391 16 1 7900000 Gain RNPS1 Diffuse large b-cell lymphoma
33 99692 16 28100000 36600000 Loss Diffuse large b-cell lymphoma
34 102840 16 57400000 90354753 Gain Diffuse large b-cell lymphoma
35 102843 16 57400000 90354753 Loss Diffuse large b-cell lymphoma
36 104071 16 66700000 70800000 Gain DDX19 Diffuse large b-cell lymphoma
37 104073 16 66700000 70800000 Gain FUK Diffuse large b-cell lymphoma
38 104075 16 66700000 70800000 Gain SIAT4B Diffuse large b-cell lymphoma
39 106530 16 88700000 90354753 Gain Diffuse large b-cell lymphoma
40 106806 17 1 22200000 Loss Diffuse large b-cell lymphoma
41 111431 17 3600000 6800000 Loss TP53 Diffuse large b-cell lymphoma
42 120634 18 2900000 78077248 Gain Diffuse large b-cell lymphoma
43 121454 18 43500000 48200000 Gain Diffuse large b-cell lymphoma
44 121719 18 46400000 52000000 Gain BCL2 Diffuse large b-cell lymphoma
45 122173 18 53800000 56200000 Gain MALT1 Diffuse large b-cell lymphoma
46 123098 18 66800000 68700000 Loss Diffuse large b-cell lymphoma
47 123108 18 66900000 71300000 Gain Diffuse large b-cell lymphoma
48 127687 19 35500000 38300000 Gain KIRREL2 Diffuse large b-cell lymphoma
49 127689 19 35500000 38300000 Gain MLL4 Diffuse large b-cell lymphoma
50 127691 19 35500000 38300000 Gain NPHS1 Diffuse large b-cell lymphoma

Expression for Diffuse Large B-Cell Lymphoma

Search GEO for disease gene expression data for Diffuse Large B-Cell Lymphoma.

Pathways for Diffuse Large B-Cell Lymphoma

Pathways related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.75 IRF4 MDM2 MYC MYD88 TP53
2
Show member pathways
12.65 CARD11 MALT1 MDM2 REL TP53
3 12.43 EZH2 FOXP1 MDM2 MYC TP53
4
Show member pathways
12.42 MDM2 MYC REL TP53
5
Show member pathways
12.33 MDM2 MYC REL TP53
6
Show member pathways
12.3 CDK4 MDM2 MYC TP53
7
Show member pathways
12.3 CARD11 CDK4 IRF4 MALT1 REL
8 12.29 CDK4 MDM2 MYC TP53
10 12.21 CDK4 MDM2 REL TP53
11
Show member pathways
12.17 BCL6 CARD11 IRF4 MALT1 MYC REL
12 12.1 CDK4 MDM2 MYC TP53
13 12.07 CDK4 MDM2 MYC TP53
14
Show member pathways
12.06 CDK4 MDM2 MYC TP53
15 12 BCL6 LMO2 MDM2 MYC REL TP53
16 11.99 BCL6 MDM2 PRDM1 TP53
17 11.9 BCL6 MDM2 MYC TP53
18 11.88 BCL6 IRF4 MYC TP53
19 11.86 CDK4 MDM2 MYC TP53
20 11.82 CARD11 MALT1 MYD88
21
Show member pathways
11.8 IRF4 MYD88 REL
22 11.8 CDK4 MYC TP53
23 11.74 BCL6 CARD11 IRF4 MALT1 MYD88 PRDM1
24 11.73 CDK4 MYC TP53
25 11.68 CDK4 MDM2 MYC TP53
26
Show member pathways
11.66 MDM2 PRDM1 TP53
27 11.57 CDK4 MDM2 MYC TP53
28
Show member pathways
11.51 MDM2 REL TP53
29 11.33 CDK4 MDM2 MYC TP53
30 11.28 BCL6 CD5 MME PRDM1 TNFRSF8
31 11.23 CDK4 MDM2 TP53
32 11 MDM2 MYC TP53
33 11 CDK4 MDM2 MYC REL TP53
34
Show member pathways
10.98 MDM2 MYC TP53

GO Terms for Diffuse Large B-Cell Lymphoma

Cellular components related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.8 CDK4 MALT1 MDM2 MYC MYD88 TP53
2 nucleoplasm GO:0005654 9.73 BCL6 CDK4 EZH2 FOXP1 IRF4 LMO2
3 transcription factor complex GO:0005667 9.67 CDK4 LMO2 REL TP53
4 nucleus GO:0005634 9.53 BCL6 CDK4 EZH2 FOXP1 IRF4 LMO2
5 CBM complex GO:0032449 9.16 CARD11 MALT1
6 cytoplasm GO:0005737 10.13 CARD11 CDK4 EZH2 FOXP1 GCSAM MALT1

Biological processes related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.91 MDM2 MYC MYD88 PRDM1 TP53
2 negative regulation of transcription, DNA-templated GO:0045892 9.91 BCL6 EZH2 FOXP1 MDM2 PASD1 TP53
3 negative regulation of apoptotic process GO:0043066 9.88 BCL6 MALT1 MDM2 MYC MYD88 TP53
4 negative regulation of transcription by RNA polymerase II GO:0000122 9.87 BCL6 EZH2 MDM2 MYC PRDM1 REL
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.78 CARD11 MALT1 MYD88 REL
6 regulation of inflammatory response GO:0050727 9.74 BCL6 FOXP1 MYD88
7 positive regulation of smooth muscle cell proliferation GO:0048661 9.71 FOXP1 MYC MYD88
8 regulation of cell proliferation GO:0042127 9.65 BCL6 CDK4 EZH2 MYD88 PRDM1
9 cellular response to estrogen stimulus GO:0071391 9.6 MDM2 MYC
10 replicative senescence GO:0090399 9.59 MME TP53
11 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.58 CARD11 IRF4
12 positive regulation of histone deacetylation GO:0031065 9.58 BCL6 TP53
13 cellular response to phorbol 13-acetate 12-myristate GO:1904628 9.56 CDK4 MYC
14 negative regulation of B cell apoptotic process GO:0002903 9.55 BCL6 FOXP1
15 negative regulation of gene expression GO:0010629 9.55 EZH2 MDM2 MYC PRDM1 REL
16 regulation of tumor necrosis factor production GO:0032680 9.52 FOXP1 MYD88
17 heart valve development GO:0003170 9.49 MDM2 PRDM1
18 cellular response to ionomycin GO:1904637 9.46 CDK4 FOXP1
19 cellular response to actinomycin D GO:0072717 9.37 MDM2 TP53
20 regulation of gene expression GO:0010468 9.35 CDK4 EZH2 MDM2 MYC MYD88
21 positive regulation of cell cycle GO:0045787 8.92 CDK4 MDM2 MYC TP53

Molecular functions related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding transcription factor activity GO:0003700 9.8 BCL6 FOXP1 IRF4 MYC PRDM1 REL
2 chromatin binding GO:0003682 9.77 BCL6 EZH2 FOXP1 REL TP53
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.72 EZH2 FOXP1 IRF4 MYC PRDM1
4 RNA polymerase II transcription factor activity, sequence-specific DNA binding GO:0000981 9.71 FOXP1 LMO2 MYC TP53
5 protein self-association GO:0043621 9.26 FOXP1 MALT1 MYD88 TP53
6 sequence-specific DNA binding GO:0043565 9.23 BCL6 EZH2 FOXP1 IRF4 MYC PRDM1
7 protein binding GO:0005515 10.11 BCL6 CARD11 CD5 CDK4 EZH2 FOXP1

Sources for Diffuse Large B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....